A different approach was taken by Si et al., using a PROTAC directed against the hematopoietic progenitor kinase 1 (HPK1), which mediates T cell dysfunction reflected by T cell exhaustion, diminished immunity against cancer cells, and shorter patient survival [112]. The gene discussed is MAP4K1; the disease is cancer.